Artemis Medicare Services Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Attractively valued vs sector (P/E 38.9x vs industry 50.2x)
- Low debt relative to equity (D/E 0.3x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ARTEMISMED · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 68.03% | 68.03% | 67.51% | 67.17% | 67.17% | 67.17% |
| FII | 0.11% | 0.10% | 0.16% | 0.21% | 0.65% | 0.31% |
| DII | 1.96% | 2.61% | 3.45% | 3.60% | 4.51% | 5.04% |
| Public | 22.72% | 22.08% | 21.76% | 21.93% | 20.59% | 20.39% |
| Govt | 7.18% | 7.18% | 7.12% | 7.09% | 7.09% | 7.09% |
Corporate Events
To consider and approve the Notice of the Postal Ballot for seeking the approval of Members of the Company for raising of funds
To consider and approve Audited Financial Results and recommendation of dividend, If any.
Dividend - Re 0.45 Per Share
Dividend - Rs 0.45 Per Share
Dividend - Re 0.45 Per Share
Latest News
All newsArtemis Medicare receives credit rating update
*Artemis Medicare receives credit rating update.* The company's latest credit assessment has been filed with the exchange, though specific rating details are not disclosed. This follows standard corporate disclosure norms for rated entities. **No financial figures or rating changes** were highlighted in the filing. 📊 *STOCKS:* $ARTEMIS | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #CreditRating
Artemis Medicare to host Q2 and H1 FY27 investor call
*Artemis Medicare to host Q2 and H1 FY27 investor call.* The company will discuss financial performance and strategic updates from the first half of FY27. No major announcements or financial figures were disclosed in the filing. The call aims to provide clarity on recent operations and future outlook. 📊 *STOCKS:* $ARTEMIS | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #Earnings
Artemis Medicare publishes notice on physical securities handling
*Artemis Medicare publishes notice on physical securities handling.* The company released a newspaper publication regarding the handling of physical securities, as part of regulatory compliance. This is a routine corporate filing with no immediate financial impact. Traders should note procedural updates for share transfers and investor communication. 📊 *STOCKS:* $ARTEMIS | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #CorporateFiling
Artemis Medicare to host investor meet on Sep 22, 2026
*Artemis Medicare to host investor meet on Sep 22, 2026.* The company will present updates to analysts and institutional investors. This event aims to enhance transparency and investor engagement. No financial announcements or strategic shifts were indicated. 📊 *STOCKS:* $ARTEMIS | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #InvestorMeet
Artemis Medicare hosts analyst call for Q1 FY27.
*Artemis Medicare hosts analyst call for Q1 FY27.* The company held an investor interaction to discuss quarterly performance and business outlook. Details on financials or guidance were not disclosed in the filing. Investors await further updates from the call transcript. 📊 *STOCKS:* $ARTEMIS | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #Earnings
Artemis Medicare to host investor meet on August 13, 2026
*Artemis Medicare to host investor meet on August 13, 2026* to discuss business updates with analysts and institutional investors. The event aims to enhance transparency and investor engagement. No financial figures or strategic announcements were disclosed. It reflects routine investor relations activity. 📊 *STOCKS:* ARTEMIS | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #InvestorMeet
Artemis Medicare publishes notice in newspaper
*Artemis Medicare publishes notice in newspaper* as part of a regulatory or corporate requirement. The filing indicates a routine disclosure, with no financial or operational details provided. Such notices are typically procedural and do not impact business fundamentals. 📊 *STOCKS:* $ARTEMISMED | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #CorporateFiling
Artemis Medicare discusses Q1 FY27 performance in investor call
*Artemis Medicare discusses Q1 FY27 performance in investor call.* The company provided updates during its analyst and institutional investor meet, covering operational and financial performance for the first quarter of FY27. No major deviations from expectations were reported. Further details were shared on business outlook and strategy. 📊 *STOCKS:* $ARTEMIS | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #Earnings
Artemis Medicare publishes notice for physical securities
*Artemis Medicare publishes notice for physical securities.* The company released a copy of a newspaper publication regarding the handling of physical securities. This is a routine corporate disclosure with no immediate financial impact. Such notices are typically issued for investor awareness and compliance purposes. 📊 *STOCKS:* ARTEMIS | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #CorporateFiling
Artemis Medicare publishes notice in newspaper
*Artemis Medicare publishes notice in newspaper* The company has released a copy of a newspaper publication as part of a regulatory requirement. **No financial figures or strategic updates** were disclosed. The filing is routine and does not indicate any immediate business change. 📊 *STOCKS:* ARTEMIS | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #corporate_filing
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹272 Cr 1.1% | ₹275 Cr 7.8% | ₹255 Cr 6.3% | ₹240 Cr 3.4% | ₹232 Cr 3.7% | ₹241 Cr 8.1% | ₹223 Cr 0.9% | ₹225 Cr |
| Op. Profit | ₹45 Cr 11.8% | ₹51 Cr 24.4% | ₹41 Cr 13.9% | ₹36 Cr 2.7% | ₹37 Cr 11.9% | ₹42 Cr 16.7% | ₹36 Cr 5.3% | ₹38 Cr |
| OPM | 16.0% 11.1% | 18.0% 12.5% | 16.0% 6.7% | 15.0% 6.3% | 16.0% 11.1% | 18.0% 12.5% | 16.0% 5.9% | 17.0% |
| Net Profit | ₹22 Cr 26.7% | ₹30 Cr 42.9% | ₹21 Cr 8.7% | ₹23 Cr 9.5% | ₹21 Cr 4.5% | ₹22 Cr 29.4% | ₹17 Cr 21.4% | ₹14 Cr |
| EPS (₹) | 1.41 34.7% | 2.16 41.2% | 1.53 8.4% | 1.67 11.3% | 1.5 7.4% | 1.62 32.8% | 1.22 17.3% | 1.04 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.1K Cr 15.4% | ₹937 Cr 6.6% | ₹879 Cr 19.3% | ₹737 Cr 32.8% | ₹555 Cr 36.0% | ₹408 Cr 27.8% | ₹565 Cr 3.3% | ₹547 Cr |
| Expenses | ₹893 Cr 13.8% | ₹785 Cr 5.2% | ₹746 Cr 16.0% | ₹643 Cr 32.0% | ₹487 Cr 30.6% | ₹373 Cr 25.8% | ₹503 Cr 4.6% | ₹481 Cr |
| Op. Profit | ₹188 Cr 23.7% | ₹152 Cr 14.3% | ₹133 Cr 41.5% | ₹94 Cr 38.2% | ₹68 Cr 94.3% | ₹35 Cr 43.5% | ₹62 Cr 6.1% | ₹66 Cr |
| OPM | 17.0% 6.3% | 16.0% 6.7% | 15.0% 15.4% | 13.0% 8.3% | 12.0% 33.3% | 9.0% 18.2% | 11.0% 8.3% | 12.0% |
| Other Income | ₹27 Cr 18.2% | ₹33 Cr 371.4% | ₹7 Cr 0.0% | ₹7 Cr 133.3% | ₹3 Cr 57.1% | ₹7 Cr 75.0% | ₹4 Cr 100.0% | ₹2 Cr |
| Interest | ₹28 Cr 12.5% | ₹32 Cr 3.2% | ₹31 Cr 55.0% | ₹20 Cr 66.7% | ₹12 Cr 7.7% | ₹13 Cr 0.0% | ₹13 Cr 18.2% | ₹11 Cr |
| Depreciation | ₹48 Cr 6.7% | ₹45 Cr 12.5% | ₹40 Cr 29.0% | ₹31 Cr 40.9% | ₹22 Cr 0.0% | ₹22 Cr 4.3% | ₹23 Cr 15.0% | ₹20 Cr |
| PBT | ₹139 Cr 28.7% | ₹108 Cr 58.8% | ₹68 Cr 33.3% | ₹51 Cr 37.8% | ₹37 Cr 362.5% | ₹8 Cr 74.2% | ₹31 Cr 16.2% | ₹37 Cr |
| Tax % | 25.0% 4.2% | 24.0% 14.3% | 28.0% 12.0% | 25.0% 56.3% | 16.0% 11.1% | 18.0% 50.0% | 36.0% 20.0% | 45.0% |
| Net Profit | ₹104 Cr 26.8% | ₹82 Cr 67.3% | ₹49 Cr 28.9% | ₹38 Cr 22.6% | ₹31 Cr 416.7% | ₹6 Cr 68.4% | ₹19 Cr 5.0% | ₹20 Cr |
| EPS (₹) | 6.55 9.2% | 6 65.7% | 3.62 25.7% | 2.88 20.0% | 2.4 389.8% | 0.49 67.1% | 1.49 53.6% | 0.97 |
| Div Payout | 7.0% 0.0% | 7.0% 41.7% | 12.0% 25.0% | 16.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|
Liabilities | |||||||||
| Equity Capital | ₹16 Cr 14.3% | ₹14 Cr 0.0% | ₹14 Cr 0.0% | ₹14 Cr 7.7% | ₹13 Cr 0.0% | ₹13 Cr 0.0% | ₹13 Cr 0.0% | ₹13 Cr 0.0% | ₹13 Cr |
| Reserves | ₹919 Cr 5.8% | ₹869 Cr 5.5% | ₹824 Cr 89.4% | ₹435 Cr 11.5% | ₹390 Cr 12.7% | ₹346 Cr 12.7% | ₹307 Cr 2.3% | ₹300 Cr 7.1% | ₹280 Cr |
| Borrowings | ₹262 Cr 6.1% | ₹279 Cr 3.8% | ₹290 Cr 9.4% | ₹320 Cr 11.9% | ₹286 Cr 42.3% | ₹201 Cr 36.7% | ₹147 Cr 30.1% | ₹113 Cr 0.9% | ₹114 Cr |
| Other Liabilities | ₹232 Cr 12.1% | ₹264 Cr 15.3% | ₹229 Cr 12.8% | ₹203 Cr 6.0% | ₹216 Cr 45.0% | ₹149 Cr 12.0% | ₹133 Cr 16.9% | ₹160 Cr 8.8% | ₹147 Cr |
| Total Liabilities | ₹1.4K Cr 0.2% | ₹1.4K Cr 5.1% | ₹1.4K Cr 39.6% | ₹972 Cr 7.4% | ₹905 Cr 27.5% | ₹710 Cr 18.3% | ₹600 Cr 2.4% | ₹586 Cr 5.8% | ₹554 Cr |
Assets | |||||||||
| Fixed Assets | ₹805 Cr 1.4% | ₹794 Cr 6.6% | ₹745 Cr 3.6% | ₹719 Cr 18.8% | ₹605 Cr 23.7% | ₹489 Cr 27.7% | ₹383 Cr 2.5% | ₹393 Cr 3.1% | ₹381 Cr |
| CWIP | ₹28 Cr 20.0% | ₹35 Cr 12.5% | ₹40 Cr 21.2% | ₹33 Cr 65.3% | ₹95 Cr 48.4% | ₹64 Cr 21.0% | ₹81 Cr 44.6% | ₹56 Cr 14.3% | ₹49 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹596 Cr 0.2% | ₹597 Cr 4.4% | ₹572 Cr 161.2% | ₹219 Cr 6.8% | ₹205 Cr 30.6% | ₹157 Cr 15.4% | ₹136 Cr 0.7% | ₹137 Cr 10.5% | ₹124 Cr |
| Total Assets | ₹1.4K Cr 0.2% | ₹1.4K Cr 5.1% | ₹1.4K Cr 39.6% | ₹972 Cr 7.4% | ₹905 Cr 27.5% | ₹710 Cr 18.3% | ₹600 Cr 2.4% | ₹586 Cr 5.8% | ₹554 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹132 Cr 9.6% | ₹146 Cr 33.9% | ₹109 Cr 14.2% | ₹127 Cr 111.7% | ₹60 Cr 122.2% | ₹27 Cr 51.8% | ₹56 Cr 40.0% | ₹40 Cr |
| Investing CF | ₹-90 Cr 76.6% | ₹-385 Cr 337.5% | ₹-88 Cr 44.3% | ₹-158 Cr 47.7% | ₹-107 Cr 189.2% | ₹-37 Cr 42.3% | ₹-26 Cr 48.0% | ₹-50 Cr |
| Financing CF | ₹-50 Cr 118.7% | ₹267 Cr 1020.7% | ₹-29 Cr 176.3% | ₹38 Cr 13.6% | ₹44 Cr 144.4% | ₹18 Cr 166.7% | ₹-27 Cr 292.9% | ₹14 Cr |
| Net Cash Flow | ₹-8 Cr 129.6% | ₹27 Cr 437.5% | ₹-8 Cr 214.3% | ₹7 Cr 333.3% | ₹-3 Cr 137.5% | ₹8 Cr 300.0% | ₹2 Cr 60.0% | ₹5 Cr |
| Free Cash Flow | ₹32 Cr 41.8% | ₹55 Cr 48.6% | ₹37 Cr 305.6% | ₹-18 Cr 63.3% | ₹-49 Cr 1125.0% | ₹-4 Cr 113.3% | ₹30 Cr 276.5% | ₹-17 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 40d 2.6% | 39d 0.0% | 39d 15.2% | 46d 4.2% | 48d 2.0% | 49d 0.0% | 49d 5.8% | 52d |
| Inventory Days | — | — | — | — | — | — | — | — |
| Days Payable | — | — | — | — | — | — | — | — |
| Cash Conv. Cycle | 40d 2.6% | 39d 0.0% | 39d 15.2% | 46d 4.2% | 48d 2.0% | 49d 0.0% | 49d 5.8% | 52d |
| Working Capital Days | -17d 39.3% | -28d 3.7% | -27d 37.2% | -43d 65.4% | -26d 27.8% | -36d 0.0% | -36d 29.4% | -51d |
| ROCE | 15.0% 0.0% | 15.0% 7.1% | 14.0% 27.3% | 11.0% 10.0% | 10.0% 150.0% | 4.0% 60.0% | 10.0% | — |
Source: Screener.in · Lower days = better efficiency
About Artemis Medicare Services Limited
Artemis Medicare Services Ltd (AMSL) was incorporated in 2004, operates a 541-bedded multi-specialty tertiary care hospital in Gurgaon. [1][2]
HealthcareHealthcare Services